Provenance Record

Well-structured 970-word News piece (within the 400-1200 word range for News) with Overview, What We Know, What We Don't Know, and Analysis sections. The What We Don't Know section honestly flags that neither FDA nor Sanofi has disclosed an exact injection-time figure, pricing, or rollout timeline, and raises open questions about adoption pace — this matches what the sources actually omit, not a padding exercise.

All four sources fetched successfully (HTTP 200) and sha256-verified against the manifest; I decompressed and read each snapshot in full. source-0.html.gz (fda.gov): confirmed the July 9, 2026 approval date, isatuximab-irfc/Sarclisa Escena naming, all three combination regimens verbatim (Pd for ≥1 prior line incl. lenalidomide+PI; Kd for 1-3 prior lines R/R; VRd for transplant-ineligible NDMM), 1,400 mg dose, CirCLIQ OBDS + manual syringe/infusion-set delivery options, orphan drug designation, IRAKLIA (NCT05405166) 531-patient randomization and ORR figures (71.1%/70.5%), IZALCO (NCT05704049) 74-patient/79.7% ORR, and IsaSocut (NCT05889221) 74-patient/97.3% ORR. source-1.html.gz (Sanofi press release, globenewswire.com, on allowlist): confirmed the Cincinnati-based Enable Injections attribution, enFuse platform, retractable 30g needle spec, exact ORR patient counts (187/263 vs 189/268), relative risk 1.008 with 95% CI 0.903-1.126, systemic administration reaction rates (25% IV vs 1.5% SC), injection site reaction rate (0.4%, 19/5,145 injections, nearly all grade 1 except one grade 2), the five most common adverse reactions (URI, fatigue, pneumonia, musculoskeletal pain, diarrhea), verbatim quotes from Sikander Ailawadhi, Manuela Buxo, and Donna D. Catamero, the ~60-country/four-indication/70,000-patient figures, EU/UK approval, and Japan's manual-injection approval with the OBI submission still under review. source-2.html.gz (pharmexec.com, not on allowlist) and source-3.html.gz (drugdeliverybusiness.com, not on allowlist): both independently corroborate the clinical figures, device specs, and all three quotes with no discrepancies; drugdeliverybusiness.com additionally confirms the Cincinnati HQ and enFuse/CirCLIQ relationship. No claim in the article is unsupported by at least one, and typically two or three, of the four snapshots. No hallucinated quotes, no fabricated specifics, no misattribution found.

Every number in the article (dose, patient counts, ORR percentages, relative risk, confidence interval, reaction rates, injection counts, country/patient totals) traces exactly to the FDA and/or Sanofi snapshots. No discrepancies found between the article and any of the four sources.

Clean, well-sourced, appropriately hedged News article. All four sources personally read from disk snapshots and cross-verified against each other with no discrepancies. Verdict upgraded from the script's auto-suggested APPROVE_WITH_CORRECTIONS to APPROVE because the sole finding is an allowlist-configuration gap, not a factual or attribution problem a reader-facing correction could meaningfully address.